Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Have you utilized JAK inhibitors in patients on dialysis?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How would you approach management of an elderly patient with known mantle cell lymphoma and new diagnosis of cryoglobulinemic vasculitis with mild skin involvement, fatigue, arthralgias but no other major organ involvement?
How would you approach management of a patient with ankylosing spondylitis who was doing well on tofacitinib, but experienced a STEMI while on therapy?
